Novartis has informed the Food and Drug Administration (FDA) of the discontinuation of Famvir (famciclovir).
The reason for the discontinuation is not due to manufacturing, product quality, safety or efficacy concerns. The discontinued products include the 125mg (NDC 0078-0366-15), 250mg (NDC 0078-0367-15), and 500mg (NDC 0078-0368-15) tablets in 30-count bottles. Also discontinued is the 500mg (NDC 0078-0368-64) single-unit package of 50.
Famvir, a prodrug of penciclovir, is a nuceloside analog DNA polymerase inhibitor indicated for the treatment of herpes labialis, genital herpes, and herpes zoster in immunocompetent adult patients. In HIV infected adults it is indicated to treat recurrent episodes of orolabial or genital herpes.
For more information visit the FDA.gov.